Exelixis Inc (EXEL) News
Latest headlines that mention EXEL, newest first · each headline opens the original publisher
- Last price
- $64.58
- Day change
- +0.30%
- Next earnings
- 2026-10-29 AMC
EXEL headlines
latest coverageExelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment. The post Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay appeared first on Investor's Business Daily .
Exelixis is Friday's IBD Stock Of The Day. Shares have recovered from a post second-quarter drop and are now trading in a buy zone. The post IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out appeared first on Investor's Business Daily .
Cancer treatment name Exelixis is attempting to clear a flat base with a 57.57 pivot. The post Cancer Stock Breaks Out To Highs; Key FDA Action On Watch appeared first on Investor's Business Daily .
Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.
Exelixis stock toppled late Wednesday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations. The post Why This Top-Ranked IBD 50 Stock Just Plummeted On Its Earnings appeared first on Investor's Business Daily .
Here are today’s top growth stocks that have just been added to the IBD stock lists, including the IBD 50, IPO Leaders and the IBD Big Cap 20. The post Amazon Stock, Exelixis And CrowdStrike Among 17 New Stocks On IBD Watchlists appeared first on Investor's Business Daily .
EXEL news alerts
Get an alert by email or push when a new headline mentions EXEL.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.